Wanbury Limited reports 11.6% growth in revenue for Q2 FY25, EBITDA surges 19.6%

Wanbury Limited, a leading pharmaceutical company with a global footprint in active pharmaceutical ingredients (APIs) and domestic branded formulations, has announced a stellar financial performance for the second quarter of FY25. The company reported an 11.6% increase in revenue from operations, reaching ₹161.2 crore, compared to ₹144.5 crore in Q2 FY24. Its EBITDA jumped by an impressive 19.6%, standing at ₹21.6 crore, with an enhanced EBITDA margin of 13.4%.

This growth was primarily driven by increased sales volumes of key API products like Metformin and Sertraline and robust sales in its branded formulations segment. The company’s PAT also saw an 8.9% rise, touching ₹8 crore.

Expansion and regulatory compliance bolster growth

Wanbury’s Patalganga manufacturing facility emerged as a cornerstone for growth, receiving a USFDA Establishment Inspection Report with a “No Action Indicated” designation, confirming regulatory compliance. Additionally, the facility was honoured with two safety awards from the Maharashtra State Government for the third consecutive year.

Meanwhile, the Tanuku facility is undergoing upgrades, slated for completion by December 2024. This renovation aims to enhance capacity and cost efficiency, preparing the company for accelerated production and growth.

Director highlights strategic focus

Director Mohan Rayana attributed the strong quarterly results to strategic sales initiatives and process improvements. He emphasised Wanbury’s plan to launch three new API products soon, alongside its efforts to expand its reach across geographies. The company has also secured a Certificate of Suitability (CEP) for Dextromethorphan API, enabling entry into the European market.

Rayana reiterated the company’s focus on cost optimisation through process engineering to drive margin growth while maintaining its commitment to safety and quality.

About Wanbury: A legacy of innovation

Founded in 1988, Wanbury Limited operates with USFDA and EUGMP-certified facilities and exports APIs to over 50 countries. Its API portfolio includes high-demand products like Metformin, Sertraline, and Tramadol, serving leading global generic players. In the branded formulations segment, Wanbury maintains a strong presence across therapeutic areas such as gynaecology, orthopaedics, and gastroenterology.